NYMOX PHARMACEUTICAL CORP (NYMX)

BSP733981026 - Common Stock

0.2  -0.05 (-19.68%)

After market: 0.1767 -0.02 (-11.65%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

NYMOX PHARMACEUTICAL CORP

NASDAQ:NYMX (7/6/2023, 7:10:50 PM)

After market: 0.1767 -0.02 (-11.65%)

0.2

-0.05 (-19.68%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap18.10M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NYMX Daily chart

Company Profile

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. The company is headquartered in Saint-Laurent, Quebec. The firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (prostate enlargement, BPH) and for low-grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company’s lead drug candidate for BPH FT has completed Phase III development in more than 70 clinical centers in the United States. FT has completed a phase II trial in the United States. The company has also developed the AlzheimAlert test. The firm operates in Canada, the United States and Switzerland.

Company Info

NYMOX PHARMACEUTICAL CORP

St. Laurent, 9900 Cavendish Blvd Suite 306

Saint-Laurent QUEBEC H4M 2V2

P: 18009369669.0

CEO: Paul Averback

Employees: 3

Website: https://nymox.com/

NYMX News

News Image7 months ago - Nymox Pharmaceutical CorporationNymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results

NYMOZARFEX 15 mg Minimal Treatment of Low Grade Prostate Cancer Leads to Significant Long-Term Reduction in Incidence of Associated Prostate Cancer Surgery and Radiotherapy

News Image7 months ago - Nymox Pharmaceutical CorporationNymox Reports on U.S. Patent Issuances
News Image8 months ago - Nymox Pharmaceutical CorporationNymox Update
News Image8 months ago - Nymox Pharmaceutical CorporationNymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox
News Image8 months ago - Nymox Pharmaceutical CorporationNYMOX Update
News Image8 months ago - InvestorPlaceWhy Is Kazia Therapeutics (KZIA) Stock Moving Today?

Kazia Therapeutics (KZIA) stock is on the move Thursday after the company received fast-track designation for its paxalisib program.

NYMX Twits

Here you can normally see the latest stock twits on NYMX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example